PedAM
Pediatric Disease Annotations & Medicines
| Disease | esophagitis |
| Phenotype | C0017168|gastroesophageal reflux disease |
| Sentences | 13 |
| PubMedID- 23724182 | We decided to investigate the association between nicotinine, one of the nicotine metabolites and esophagitis in children with gastroesophageal reflux disease (gerd). |
| PubMedID- 19800099 | Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the esohisto project. |
| PubMedID- 19241170 | Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. |
| PubMedID- 24348570 | The treatment consists of the management of comorbidities and the underlying esophagitis, with measures for gastroesophageal reflux disease, alcohol withdrawal, and antibiotic treatment for associated infections [2, 4, 5, 11]. |
| PubMedID- 23476803 | Pantoprazole, a proton pump inhibitor (ppi), is indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease (gerd). |
| PubMedID- 23898378 | esophagitis is defined as inflammation of the esophagus, with gastroesophageal reflux disease (gerd) being the most common cause.1 a wide variety of other identifiable causes of esophagitis exists, including eosinophilic, infectious, toxic ingestions, radiation effects, and causes related to mucocutaneous disease. |
| PubMedID- 23935715 | The subjects were required to have no evidence of peptic ulcer disease or gastroesophageal reflux disease with or without esophagitis, malignancy and pancreaticobiliary disease. |
| PubMedID- 20843755 | Prevalence of eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease symptoms: a prospective study. |
| PubMedID- 22832034 | Intravenous esomeprazole is approved in the united states for the short-term treatment of gastroesophageal reflux disease (gerd) with erosive esophagitis in adults and in pediatric patients 1 month to 17 years of age (inclusive) as an alternative to oral therapy. |
| PubMedID- 20949704 | (hh), or esophagitis in patients with suspected gastroesophageal reflux disease (gerd). |
| PubMedID- 20818348 | However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (gerd). |
| PubMedID- 21655746 | Eosinophilic esophagitis in patients with typical gastroesophageal reflux disease symptoms refractory to proton pump inhibitor. |
| PubMedID- 21991513 | The prevalence of esophagitis in children with known gastroesophageal reflux disease (gerd) is estimated at 15–62% [4–6] and there can be an overlap in the symptoms associated with gerd and cd. |
Page: 1